New Alzheimer's Drug Trial Tests Immune Approach
A Phase 2 study is now evaluating an intranasal treatment to see if it can slow early-stage Alzheimer's disease.
Updated on Oct. 16, 2026 in Alzheimer’s
Live Poll
Should Alzheimer's research prioritize targeting neuroinflammation alongside current amyloid-clearing therapies?
Tiziana Life Sciences has completed the initial dosing for participants in a Phase 2 trial testing an intranasal treatment for early-stage Alzheimer's disease. The study evaluates the safety and efficacy of foralumab as a standalone therapy and in combination with existing drugs.
Why it matters
Researchers are investigating whether targeting chronic neuroinflammation can slow the progression of Alzheimer's. This trial explores a novel approach by using intranasal delivery to modulate the immune response in the brain.
This Phase 2 randomized, placebo-controlled trial is currently evaluating the safety and efficacy of intranasal foralumab in patients with early or mild Alzheimer's disease. Results regarding cognitive function and biomarkers are not yet known.
The players
Tiziana Life Sciences
A biotechnology company focused on the development of immunomodulation therapies using human monoclonal antibodies.
Brigham and Women's Hospital
A teaching hospital that hosts the Ann Romney Center for Neurologic Diseases, a major hub for Alzheimer's and brain research.
The details
The treatment involves a human anti-CD3 monoclonal antibody designed to induce regulatory T cells that target activated microglia. By addressing these immune cells in the brain, researchers hope to reduce neuroinflammation, which is a hallmark of Alzheimer's pathology. The study is also testing whether this approach performs effectively when paired with existing medications like lecanemab or donanemab, with endpoints measured through cognitive testing and TSPO-PET imaging.
Timeline
Dosing for all trial participants was completed in October 2026.
Topline data from the trial is expected in the first quarter of 2027.
Health Landscape
This study aligns with the broader research initiatives at the Ann Romney Center for Neurologic Diseases, which focuses on identifying new ways to address neurodegenerative conditions. It represents a shift toward exploring immune-modulating treatments to complement existing amyloid-targeting therapies.
This development is currently limited to a clinical trial and is not available for patient use or clinical practice. Individuals interested in participating in future Alzheimer's research should discuss current trial enrollment opportunities with their neurologist.
The takeaway
This trial represents an evolving approach to Alzheimer's by targeting neuroinflammation via the immune system. Patients should continue to discuss approved management strategies and potential clinical trial eligibility with their care team.
What happens next
Topline trial data is expected in the first quarter of 2027.
Further reading
For more information on current treatment paths, visit Alzheimer’s.
Live Poll
Should Alzheimer's research prioritize targeting neuroinflammation alongside current amyloid-clearing therapies?
